CURX — Curanex Pharmaceuticals Balance Sheet
0.000.00%
Annual balance sheet for Curanex Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 0.002 | 0.074 | 0.149 | 4.97 |
| Net Total Receivables | 0.003 | 0 | — | — |
| Total Inventory | ||||
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 0.01 | 0.074 | 0.518 | 11.2 |
| Net Property, Plant And Equipment | — | — | — | 0.353 |
| Total Assets | 0.01 | 0.074 | 0.518 | 11.6 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0 | 0.014 | 0.015 | 0.137 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 0 | 0.014 | 0.015 | 0.361 |
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 0.01 | 0.06 | 0.503 | 11.2 |
| Total Liabilities & Shareholders' Equity | 0.01 | 0.074 | 0.518 | 11.6 |
| Total Common Shares Outstanding | ||||
| Total Preferred Shares Outstanding |